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Abstract In the present study, poly(ethylene glycol)-b-poly
(ε-caprolactone) micelles loaded with etoposide (ETO)
were formulated and further conjugated with pentapeptide
Glu-Ile-Leu-Asp-Val (EILDV) to target α4β1 integrin
receptor overexpressed on metastatic tumor cell. Using a
distinct ratio of carboxyl-terminated poly(ethylene glycol)-
block-poly(ε-caprolactone) (HOOC–PEG-b-PCL) to
methoxy-poly(ethylene glycol)-block-poly(ε-caprolactone
(CH3O–PEG-b-PCL) polymers, we formulated a series of
micellar formulations having different surface densities of
EILDV and observed optimum cellular uptake of micelles
with 10% EILDV surface density by B16F10 cells. The
cytotoxicity of EILDV-conjugated micelles was observed
close to 1.5-fold higher than plain ETO after 72 h of drug
incubation, demonstrating controlled release of drug inside
the cell after enhanced intracellular uptake with the ability
to selectively target cancer cells. In addition, EILDV-
conjugated micelles inhibited the migration of B16F10
cells effectively compared with plain ETO and non-
conjugated micellar formulations when cells were treated
with equivalent cytotoxic concentration of the drug, i.e.,
IC25. B16F10 cells treated with EILDV-conjugated micelles
showed a significant reduction in the attachment of cells to
the substrate-coated plate compared with non-conjugated
micellar formulations, implying retention of the biological
activity of EILDV after coupling to micelles. Furthermore,
the in vivo experimental metastasis assay conducted on
C57BL/6 mice demonstrated significant activity of EIDLV-
conjugated micelles in the reduction of pulmonary metastatic
nodule formation in both pretreatment and post-treatment
methods. In conclusion, EIDLV-conjugated micelles showed
higher efficacy in the treatment of metastasis and would be a
promising approach in the treatment of metastasis.
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1 Introduction
Metastasis, the ability of cells in a primary tumor to invade
other tissues and to spread throughout the body, is the
underlying cause of most cancer deaths (Leber and Efferth
2009). Detection of cancer at an early stage before it has
spread is possible to treat successfully by surgery/local
irradiation or by chemotherapy. However, in most cases
when “primary” tumor is detected, cancer cells have
already moved from their primary site and settled in other
organs to continue their secondary growth, gaining a “head
start” in the race against malignancy that patients rarely win
(Bagi 2002). The cascade of metastasis consists of five
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basic steps: (1) invasion and migration; (2) intravasation;
(3) circulation; (4) extravasation; and (5) colonization,
proliferation, and angiogenesis (Chamber et al. 2002; Leber
and Efferth 2009). During this complex process, the
adhesive interaction of metastasizing tumor cells to the
extracellular matrix (ECM) components (fibronectin, collagen,
laminin, and vitronectin) appears a key part in metastasis
(Bidard et al. 2008; Brooks et al. 2010).
Integrins, the most important cell surface receptors that
mainly bind to ECM proteins, consist of two non-covalently
associated transmembrane glycoproteins subunits, α and β
(Janes and Watt 2006; Kuphal et al. 2005; Villard et al.
2006). There are 18 α- and 8 β-subunits of integrins, which
combine to form at least 24 different heterodimers, which are
involved in key biological processes such as adhesion,
signaling, migration, proliferation, survival, angiogenesis,
oncogenesis, and metastasis (Mizejewski 1999; Wan et al.
2009). The binding of these integrins to a particular ECM
protein during cell adhesion can be complex phenomena, but
usually involves the recognition of a specific target sequence
of the ligand (ECM components; Singleton and Menino
2005). Among various integrin receptors, the α4β1 integrin
receptor binds to two different ligands, the endothelial cell
surface protein vascular cell adhesion molecule-1 (VCAM-1)
and the extracellular matrix component fibronectin (Mould et
al. 1994). Wu et al. (1995) reported that the expression of
α4β1 integrin in the CHO cell line enables the cells to
adhere, spread, and migrate in response to VCAM-1.
Furthermore, Mould et al. (1994) also suggested an α4β1-
mediated melanoma cell adhesion and migration using
human metastatic melanoma cell lines A375-SM. The
adhesion and migration of lymphatic endothelial cells were
also promoted by α4β1 integrin during growth factor and
tumor-induced lymphangiogenesis, which facilitates tumor
metastasis (Garmy-Susini et al. 2010). It has been reported
that α4β1 integrin binds to three different site of fibronectin
(Mould et al. 1994). Two of these (represented by peptides
CS1 and CS5) are present separately and independently in
the alternatively spliced IIICS, while the third site resides in
the adjacent constitutively expressed HepII domain.
The pentapeptide sequence Glu-Ile-Leu-Asp-Val
(EILDV), present in an alternatively spliced segment of
fibronectin, is recognized by both the α4β1 and α4β7
integrins and exhibited its antimetastatic activity (Kaneda et
al. 1997; Singleton and Menino 2005; Yamamoto et al.
1994). Various other peptide analogs like cRGD and
YIGSR also showed their antimetastatic activity, but to a
lesser extent compared with EILDV (Yamamoto et al.
1994). To exert an antimetastatic effect, large amounts of
such peptides are needed due to their enzymatic degrada-
tion and rapid renal clearance in vivo (Mu et al. 1999). To
circumvent these, the bioconjugation of these peptides with
PEG and poly(styrene-co-maleic acid) has been reported to
enhance their antimetastatic activity with longer blood
circulation (Maeda et al. 1997; Mu et al. 1999; Yamamoto
et al. 1994). The utilization of EILDV as a targeting moiety
for recognition of tumor cells overexpressing the α4β1
integrin receptor could be a better alternative in tumor
targeting with possible use in conditions of tumor metas-
tasis. Various other peptides like YIGSR and cRGD have
been used as targeting moieties for nanosized carriers to
target laminin and αvβ5 receptors, respectively, and have
showed their potential greater than plain drug (Lopez-
Barcons et al. 2004; Nasongkla et al. 2004; Oba et al.
2007). To the best of our knowledge, the use of EILDV as a
targeting moiety for nanocarriers loaded with an anticancer
drug the treatment of metastasis has not been explored, and
this is the first report of an EILDV-conjugated micellar
system for active tumor targeting.
The present study was focused on the design and
development of polymeric micelles loaded with the anticancer
drug, etoposide (ETO), where EILDV was conjugated to the
surface of the micelles. Various in vitro evaluations were
carried out using highly metastatic B16F10 cell lines to assess
the effectiveness of EILDV-conjugated micellar formu-
lations. Moreover, experimental metastasis studies were
conducted using B16F10 melanoma mouse models to
examine the effect of micellar formulations in the
prevention of metastasis.
2 Materials and methods
2.1 Materials
ETO was a kind gift from Cadila Pharmaceutical Ltd.
(Ahmedabad, India). Monomethoxy poly(ethylene glycol)
of molecular weights 2 and 5 kDa, ε-caprolactone (CL),
HCl in diethyl ether (1.0 M), 2,4,6 trinitro benzenesulfonic
acid (TNBS), calcium hydride, and propidium iodide were
purchased from Sigma-Aldrich (Mumbai, India). α-Carboxy
ω-hydroxyl polyethylene glycol (HOOC-PEG-OH) of mo-
lecular weights 2 and 5 kDa were purchased from Jenkem
Technology Inc. (TX, USA). EILDV was a kind gift from
the National Institute of Research in Reproductive Health,
Mumbai, India. Toluene, dichloromethane (DCM), diethyl
ether, and triethylamine of analytical grade were purchased
from S.D. Fine-Chem Ltd., (Mumbai, India). DCM was
dried and distilled using calcium hydride before use. CL was
dried over calcium hydride for 48 h and distilled under
reduced pressure before use. Plastic wares were purchased
from Tarson Products Pvt. Ltd. (Mumbai, India). Fetal
bovine serum (FBS) was purchased from Biowest (Genetix,
India). Iscove’s minimum Dulbecco’s medium (IMDM),
MTT A.R. (3-(4,5-dimethyl-2-yl)-2,5-diphenyl tetrazolium
bromide), and RNAse were procured from Himedia Lab.
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Pvt. Ltd. (Mumbai, India). All other chemicals were of
analytical grade and used without purification.
2.2 Cell culture and animals
The B16F10 melanoma cell line was purchased from the
National Center for Cell Sciences (Pune, India) and
maintained in IMDM supplemented with 10% FBS con-
taining penicillin (100 U/ml) and streptomycin (100 μg/ml)
in a humidified atmosphere containing 5% CO2 at 37°C.
Pathogen-free female C57BL/6 mice 6–8 weeks of age
were procured from Animal House, Advanced Centre for
Treatment, Research and Education in Cancer (Navi
Mumbai, India). All animal studies were carried out under
the guidelines compiled by the Committee for the Purpose
of Control and Supervision of Experiments on Animals,
Ministry of Culture, Government of India, and all the study
protocols were approved by the Institutional Animal Ethics
Committee of the Advanced Centre for Treatment, Re-
search and Education in Cancer, Navi Mumbai. The
animals were maintained in a room (23±2°C and 60±
10% humidity) under a 12-h light/dark cycle. Food and
water were given ad libitum.
2.3 Synthesis and characterization
The synthesis of HOOC-PEG-PCL was carried out as
reported earlier with slight modifications (Kim et al. 2004;
Lee et al. 2007). The typical synthesis procedure of HOOC-
PEGx-PCLy (where x=2 kDa and y=3.5 kDa) of molecular
weight 5.5 kDa was followed as described. Briefly, 1 g of
HOOC-PEG-OH (0.5 mmol, Mn=2 kDa) was azeodistilled
twice with dry toluene (50 ml) to remove water.
Ten milliliters of dried DCM was added to HOOC-PEG-OH
followed by the addition of CL (1.74 g, 15.33 mmol) using a
syringe. The polymerization was initiated by the addition of
1.0 M solution of HCl in diethyl ether (1.5 ml, 1.5 mmol); the
reaction was maintained at 25°C for 24 h with vigorous
stirring under nitrogen atmosphere. The reaction was
terminated by the addition of 0.1 ml of triethylamine;
the copolymer was collected by precipitation of the
filtrate in cold diethyl ether and washed thrice with cold
methanol to remove residual monomer. HOOC-PEG5-
PCL7 of molecular weight 12 kDa was synthesized by a
similar method using HOOC-PEG-OH of molecular
weight 5 kDa. MPEG-PCL, i.e., MPEG2-PCL3.5 and
MPEG5-PCL7, of molecular weights 5.5 and 12 kDa
were also synthesized by a similar method using monome-
thoxy poly(ethylene glycol) of molecular weights 2 and
5 kDa, respectively. Gel permeation chromatography was
performed to determine the molecular weight and
polydispersity index as reported elsewhere (Kim et al.
2004; Shen et al. 2008).
2.4 Preparation and characterization of EILDV-conjugated
micelles
ETO-loaded polymeric micelles were prepared by co-
solvent evaporation method (Aliabadi et al. 2005). Briefly,
40 mg of MPEG2–PCL3.5 and 4.45 mg of HOOC–PEG2–
PCL3.5 or 40 mg of MPEG5–PCL7 and 4.45 mg of
HOOC–PEG5–PCL7 were dissolved in 4 ml of acetone
along with 2 mg of ETO and injected dropwise to 5 ml of
distilled water under stirring at room temperature. Stirring
was continued until complete evaporation of acetone, and
the residual amount of acetone was removed by a rotary
vacuum evaporator.
Peptide EILDV was conjugated to the prepared micelles
as described earlier with slight modifications by the
formation of an amide bond between the terminal amine
group of EILDV and the surface-free carboxyl group of
micelles (Lopez-Barcons et al. 2004). Briefly, 1-(3-dime-
thylaminopropyl)-3-ethylcarbodimide hydrochloride and N-
hydroxysuccinimide dissolved in phosphate buffer, pH 4.5,
were added to the micellar solution at a four-fold higher
molar concentration to the HOOC–PEG–PCL copolymer
used in micellar formulation and stirred at room tempera-
ture for 15 min, followed by pH adjustment to 7.5 with
0.1 N NaOH. The required amount of peptide EILDV
dissolved in PBS, pH 7.4, was added (molar ratio of
peptide/HOOC–PEG–PCL, 1:1) to the micellar solution
and incubated for 3 h under mild stirring at room
temperature. The micellar solution was dialyzed using a
dialysis tube (MWCO 12,000) against distilled water to
remove unconjugated peptide and finally filtered through a
0.45-μm membrane filter to remove non-entrapped drug
and polymer aggregates. The EILDV-conjugated micelles
prepared with polymers of molecular weights 5.5 and
12 kDa were denoted as EPCL235 and EPCL570.
Stealth micellar formulations, i.e., MPCL235 and
MPCL570, were prepared by a similar method using the
synthesized copolymers MPEG2–PCL3.5 and MPEG5–
PCL7, respectively. Percent drug entrapment of micelles was
determined by dissolving an aliquot of micelles in acetonitrile
and the absorbance of the drug quantified at 285 nm using a
UV–visible spectrophotometer (UV 1700, PharmaSpec,
Shimadzu, Japan). Particle size and the zeta potential of
micelles were determined using Zetasizer, Nano-ZS (Malvern
Inst., UK). The amount of peptide EILDV bound to micelles
was determined by the developed TNBS assay method,
measuring unconjugated peptide found in the dialysis medium
(Habeeb 1966; Snyder and Sobocinski 1975).
2.5 Cellular uptake
The effect of the different surface densities of EILDV (i.e.,
5%, 10%, and 20%) on the cellular uptake of micelles was
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investigated by formulating a series of micelles using a
blend of copolymers HOOC–PEG–PCL and MPEG–PCL
at various ratios. The cellular uptakes of EILDV-conjugated
micelles, non-conjugated micelles, and plain ETO were
quantified by an HPLC method as reported earlier (Kang et
al. 2005). Briefly, 4×104 B16F10 cells per milliliter were
added to 90-mm tissue culture plates and allowed to grow
up to 90% confluency. Cells were incubated with plain
ETO or micellar formulations (drug concentration, 20 μg/ml)
at 37°C. After 2 h, the medium was aspirated and the cells
were washed three times with ice-cold PBS to stop further
uptake. Cells were harvested using saline EDTA and
centrifuged at 1,000 rpm for 15 min. After resuspending in
PBS, cells were lysed by a probe sonicator (Branson Sonifier
S-450, USA) for 3 min at 60% duty cycle followed by the
addition of 1 ml of 6 M hydrochloric acid for the precipitation
of proteins. The mixture was extracted with 3.0 ml of
dichloromethane, vortexed for 2 min, and centrifuged for
15 min at 2,500 rpm. The upper organic layer was collected
and evaporated to dryness with N2. The residue was
reconstituted in 80 μl mobile phase and analyzed using
HPLC.
The HPLC system was composed of a UV–visible detector
(SPD-20A, Prominence), sampling injector (model 231 XL,
Gilson), and a syringe pump (model 402, Gilson). The
separation was performed on a reverse-phased C18 HPLC
column (Phenomenex Luan 5μ C18 (2) 250×4.6-mm i.d.,
5 μm). The mobile phase, acetonitrile/water/glacial acetic acid
(35:61:1, v/v/v), was run at a flow rate of 1 ml/min and the
column effluent monitored by a UV detector set at 254 nm.
Diazepam was used as an internal standard and the samples
extracted using a liquid–liquid extraction process. The protein
content in the cell lysate was measured by the Bradford’s
method using bovine serum albumin (BSA) as a standard.
The percentage uptake of drug was calculated using the
following formula as reported earlier (Yuan et al. 2008):
Drug uptake percentage ð%Þ ¼ C=M
Ci=Mi
 100
where C is the intracellular concentration of ETO measured
by HPLC, M is the unit weight (in milligrams) of cellular
protein after incubation, Ci is the initial concentration of
ETO, and Mi is the initial unit weight (in milligrams) of
cellular protein.
2.6 Cytotoxicity assay
The cytotoxicity of ETO-loaded, EILDV-conjugated and
non-conjugated micelles against B16F10 cells was assessed
by the MTT assay (Dua and Gude 2006). Briefly, B16F10
cells were seeded in 96-well plates at a density of
4,000 cells/100 μl per well. The cells were allowed to
grow and stabilize for 24 h at 37°C with 5% CO2.
Subsequently, the cells were exposed to a series of doses
of plain ETO and micellar formulations and incubated for
24 h. Post-treatment cells in each well were washed with
PBS, and to this, 20 μl of MTT in PBS (5 mg/ml) and 80 μl
of complete media were added and incubated for 4 h at 37°C.
Plates were then centrifuged at 1,500 rpm for 20 min. The
medium was aspirated from the wells, and 100 μl of DMSO
was added to each well and kept on a shaker for 10 min to
dissolve formazan crystals. The optical density was measured
using an ELISA plate reader (Molecular Devices, Spectra
Max 190 with Softmax Pro) at 540 nm with a reference
wavelength of 690 nm. Cytotoxicity studies at time points of
48 and 72 h were carried out by seeding B16F10 cells at a
density of 2,000 cells/100 μl per well and 1,500 cells/100 μl
per well, respectively. The IC50 values of various formula-
tions were calculated by plotting a graph of percent cell
viability vs. concentrations.
2.7 Cell migration assay
Cell migration assay was performed to estimate the
migration of B16F10 cells after drug treatment (Dua and
Gude 2008). B16F10 cells at a density of 2×104 cells/ml in
complete medium were added to 40-mm tissue culture
plates and incubated for 48 h. The cell monolayer was
treated with ETO and micellar formulations at half IC50
(48 h) concentration and incubated at 37°C with 5% CO2
for 48 h. Wounds were created with a sterile plastic tip and
the peeled off cells removed by washing with PBS twice. A
0-h time point wound created plate was kept as the
reference plate and fixed immediately. Remaining plates were
incubated for 48 h in the presence of IMDM containing 0.1%
FBS (to allow cell migration only and not proliferation). The
plates were fixed with cold methanol and stained with 0.5%
crystal violet. Migration of cell from the edge of the injured
monolayer was measured using Laser Capture Microdissec-
tion Microscope (LCMM, Zeiss, Germany) along with Palm
Robo software at 25 different positions. The experiment was
performed six times, and percent cell migration was calculated
using following equation:
%Cell migration
¼ Zero hour wound width treated wound width
Zero hour wound width untreated wound width  100
2.8 Cell adhesion study
B16F10 cell adhesion after treatment with plain ETO and
micellar formulation to substrate-coated plates was carried
out as reported earlier, with slight modifications (Dua et al.
2007; Lopez-Barcons et al. 2004). Briefly, flat-bottom 96-well
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plates were coated with 50 μl of EILDV (0.2 mg/ml in PBS)
and the plates incubated overnight at 37°C. Plates were
washed with PBS and the uncoated space blocked with 1%
BSA in PBS and incubated for 2 h at 37°C. Plates were again
washed with PBS, and to these, substrate-coated plates, 3×
105 cells/ml in IMDM containing 0.1% BSA treated with
plain ETO and micellar formulations for 48 h at a dose of half
IC50 values (48 h) were added. Cells were further incubated
at 37°C for 1 h, and non-adherent cells were removed giving
two washes with PBS. The adherent cells were quantified
using the MTT assay and expressed as the relative percent
adhesion to the respective total unwashed cells.
2.9 Confocal microscopy
B16F10 cells at a density of 2×104 cells/ml were seeded in
40-mm tissue culture plates containing heat sterilized
coverslips. When cells reached 70% confluency, these were
treated with 6-coumarin-loaded micellar formulations
(300 μg/ml) in complete media for 1 h (Panyam et al.
2003). Cells were washed with PBS twice and fixed with
4% paraformaldehyde in PBS for 15 min at 37°C. Cover-
slips were mounted using 4% DABCO (fluorescent
mounting medium), and confocal images were taken using
FITC filter (Ex (λ) 495 nm, Em (λ) 520 nm) by a confocal
laser scanning microscope (Zeiss LSM S10 Meta).
2.10 In vitro treatment of B16F10 melanoma cells
and its effect on inhibition of lung metastasis (pretreatment)
The in vitro-treated B16F10 cell-induced metastasis was
performed as reported previously (Ratheesh et al. 2007).
Briefly, sub-confluent B16F10 cells were treated with plain
ETO and micellar formulations at a subtoxic dose (IC25
value, 48 h) and incubated for 48 h at 37°C. After two
washes with PBS, the cells were harvested and 0.1 ml of
PBS containing 0.1 million B16F10 cells (control and
treated) were inoculated to C57BL/6 mice via the tail vein.
The mice were randomly assigned to six groups (five mice/
group); one group was assigned as a control which received
untreated B16F10 cells. All mice were killed on the 21st
day of cell inoculation; their lungs were excised and the
numbers of pulmonary metastatic nodules (lung colonies)
on the surface of the lung were counted under a dissecting
microscope. The percent inhibitions in pulmonary meta-
static nodule formation were calculated with respect to the
number of nodules present in the untreated control group.
2.11 In vivo treatment of B16F10 melanoma and its effect
on inhibition of lung metastasis (post-treatment)
C57BL/6 mice were injected with 0.1 million B16F10 cells
in 0.1 ml of PBS through intravenous route by the tail vein
(Sant et al. 2000). One group received only B16F10 cells
and served as a control. On the next day of cell inoculation,
plain ETO and micellar formulations were injected at a
drug dose of 2 mg/kg intravenously via the tail vein. The
animals were killed on the 21st day of cell inoculation and
the lungs removed. The numbers of pulmonary metastatic
nodule formation on the surface of the lungs were
calculated and compared with the untreated control for
percent inhibition in pulmonary metastatic nodule formations.
2.12 Histopathology study
After counting the pulmonary metastatic nodules, the lungs
were fixed in 10% buffered formaldehyde. The tissue was
processed through a histological routine with a Shandon
Pathcentre Tissue Processor. Paraffin sections were cut
at 5-μm thickness and stained with hematoxilin and eosin.
The tissue morphology was studied under Zeiss AxioImager
Z-1 microscope and images taken.
2.13 Statistical analysis
The statistical significance of the results was analyzed using
SPSS (version 16). Differences between experimental
groups were compared using ANOVA followed by a
Bonferroni post hoc test.
3 Results
3.1 Characterization of synthesized copolymer
and EILDV-conjugated micelles
PEG–PCL block copolymers of different molecular weights
were prepared by ring opening polymerization of CL with
PEG using HCl in diethyl ether as a catalyst. The molecular
weights of HOOC–PEG2–PCL3.5 and HOOC–PEG5–
PCL7 obtained by GPC were 5.8 and 12.8 kDa, respec-
tively, while for MPEG2–PCL3.5 and MPEG5–PCL7, the
molecular weights found were 5.9 and 12.6 kDa, respec-
tively. The polydispersity index of the synthesized poly-
mers was observed between 1.2 and 1.4. In addition, the
GPC chromatogram exhibited only a single peak, which
indicated that all the impurities were removed after
purification (data not shown). Co-solvent evaporation
(nanoprecipitation) method was employed for the fabrica-
tion of micellar formulations using a blend of MPEG–PCL
and HOOC–PEG–PCL of similar molecular weight for the
formulation of EILDV-conjugated micelles. To control the
density of peptide on the surface of micelles, the HOOC–
PEG–PCL copolymer was used at 10% to the total weight
of polymer in the formation of micelles. Table 1 represents
the characterization of micellar formulations. A major
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difference in particle size between the two groups of
micelles (MPCL235 and EPCL235 to MPCL570 and
EPCL570) was found due to differences in the molecular
weights of the polymer used. The zeta potential of
EPCL235 and EPCL570 were found at a lower value
comparable to MPCL235 and MPCL570 due to the
presence of two carboxyl groups in the EILDV peptide
despite the utilization of a free carboxyl group of polymer
for the conjugation of peptide (Table 1). Entrapment
efficiency and the percent drug loading content of micelles
were dependent on the molecular weights of the polymers
utilized. The conjugation efficiency of EILDV to polymeric
micelles was found >85% at a 1:1 molar ratio of peptide to
functional polymer, i.e., HOOC–PEG–PCL.
3.2 Cellular uptake
The amount of ETO accumulated in B16F10 cells after
incubation with plain ETO and micellar formulations was
determined by a reverse-phased HPLC method. Since it is
important to know the effect of the surface density of
peptide on the cellular internalization of micelles, the
present study was conducted using micelles with various
EILDV surface densities. EILDV conjugated on the surface
of micelles with different surface densities (5%, 10%, and
20%) showed different cellular uptakes, as represented in
Fig. 1. Plain ETO showed maximum cellular uptake of
75.0±5.23% because of its solubilized state which helped
in the rapid diffusion of the drug into the cell. Compared
with plain ETO, micellar formulations showed cellular
uptakes <16%. EILDV-conjugated micelles EPCL235 and
EPCL570 exhibited higher cellular uptakes due to
receptor-mediated uptake compared with MPCL235 and
MPCL570. An increase in the cellular uptake of micelles
was also observed upon increasing the surface density of
EILDV from 5% to 20%. However, we observed a modest
increase in cellular uptake upon increasing the surface
density from 10% to 20%. Based on the results obtained in
cellular uptake studies of EILDV-conjugated micelles,
further experiments were conducted with micelles having
10% EILDV surface density.
3.3 Cytotoxicity assay
The cytotoxicity of EILDV-conjugated and non-conjugated
micellar formulations were carried out on B16F10 cell line
by the MTT assay with different drug concentrations and
incubation times. Table 2 presents the IC50 values obtained
after plotting a graph of percent cell viability vs. concen-
trations. After 24 h of drug incubation, plain ETO showed
higher cytotoxicity at all concentrations compared with
micellar formulations, and the IC50 value obtained was
significantly lower (P<0.001). After 48 h of drug incuba-
tion, an increase in the cytotoxicity of ETO was observed
(Table 2), which was still higher compared with all micellar
formulations. The micellar formulations showed an increase
in cytotoxicity up to 40- to 50-fold after 48 h of drug
incubation compared with 24 h of drug incubation,
indicating the controlled-release properties of micelles after
intracellular uptake. An increase in the drug incubation time
Fig. 1 Percent cell uptake of ETO after incubation of plain ETO and
micellar formulations with B16F10 cells for 2 h. EPCL235 and
EPCL570 micellar formulations used for cell uptake studies were with
different EILDV surface densities (5%, 10%, and 20%). Results are
the mean ± SD, n=6 (*P<0.05, **P<0.01 compared with MPCL235;
#P<0.05, ##P<0.01 compared with MPCL570)















EPCL235 46.2±4.5 0.176 −8.7±1.9 75.3±3.6 3.39±0.16 85.3±7.4
EPCL570 80.3±4.8 0.198 −9.3±2.2 83.9±4.9 3.77±0.22 89.2±6.3
MPCL235 38.5±2.5 0.152 −4.0±0.4 81.1±2.0 3.90±0.10 –
MPCL570 73.3±4.0 0.143 −4.6±0.3 92.0±3.4 4.40±0.17 –
Results are the mean ± SD (n=3)
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up to 72 h resulted in no further increase in the cytotoxicity of
plain ETO, whileMPCL235 andMPCL570micelles exhibited
a cytotoxicity profile comparable to plain ETO. An increase in
cytotoxicity to 1.72- and 1.38-fold was observed with
EPCL235 (P<0.01) and EPCL570 micelles compared with
plain ETO. EILDV-conjugated placebo micellar formulations
and plain EILDV peptide at a maximum concentration
(350 μg/ml) showed no toxic effects against B16F10 cells
when incubated for 72 h (data not shown).
3.4 Cell migration assay
The migration of B16F10 cells toward wound created was
found to be inhibited upon treatment with a subtoxic dose
of plain ETO and micellar formulations. Figure 2 presents
the cell migration images of B16F10 cells in treated and
untreated plates after fixing and staining, in which the
maximum cell migration was observed in untreated control.
Considering the cell migration of untreated control as
100%, plain ETO showed cell migration of 41.9%, while
MPCL235 and MPCL570 micelle-treated cell showed cell
migration of 32.3% and 33.2%, respectively (Fig. 3).
B16F10 cells treated with EPCL235 and EPCL570 micelles
exhibited maximum inhibition in cell migration of 28.9%
and 21.7%, respectively, compared with plain ETO.
Placebo EILDV-conjugated micelles EPCL235-P and
EPCL570-P showed no inhibition in cell migration, and
migration showed a resemblance to untreated control.
3.5 Cell adhesion study
Percent adhesion of B16F10 cells treated with subtoxic
doses (IC25, 48 h) of plain ETO and micellar formulations
to substrate-coated plate was presented in Fig. 4. We
observed a significant reduction in cell adhesion (P<0.001)
in plain ETO and micellar formulation-treated B16F10 cells
compared with the untreated control. The adhesion of
B16F10 cells treated with plain ETO was 66.3±5.27%,
while MPCL235 and MPCL570 showed 54.84±6.37% and
61.96±8.67%, respectively (Fig. 4). A maximum inhibition
in cell adhesion was observed in EILDV-conjugated
micelles EPCL235 and EPCL570 (P<0.01), which
exhibited 1.73- and 1.62-fold reductions in cell adhesion
compared with plain ETO-treated B16F10 cells (Fig. 4).
Placebo micellar formulations EPCL235-P and EPCL570-P
also showed cell adhesions up to 81.8±3.52% and 91.5±
2.57% toward the substrate-coated plates.
3.6 Confocal microscopy
Qualitative uptake of 6-coumarin-loaded, EILDV-
conjugated and non-conjugated micellar formulations by
B16F10 cells were carried out after 1 h of incubation
(Fig. 5). It was demonstrated that compared with MPCL235
and MPCL570 micelles, a more prominent fluorescence
intensity was observed in EILDV-conjugated micelles, i.e.,
EPCL235- and EPCL570-treated B16F10 cells.
Table 2 Inhibitory concentra-
tions (50%) of various formula-
tions at different times of
incubation with B16F10 cells
Values are the mean ± SD (n=6)
***P<0.001, **P<0.01,
*P<0.05 (compared with ETO
at each time point)
Formulation code IC50 (μM)
24 h 48 h 72 h
ETO 0.087±0.010 0.050±0.004 0.043±0.003
MPCL235 4.3±0.61*** 0.082±0.011* 0.034±0.008
EPCL235 2.5±0.30** 0.055±0.007 0.025±0.001**
MPCL570 5.0±0.80*** 0.120±0.013*** 0.040±0.005
EPCL570 3.1±0.42*** 0.075±0.07 0.031±0.002
Fig. 2 Microscopic images of
migration of B16F10 cells after
treatment with a subtoxic
concentration of plain ETO and
micellar formulations. Zero-hour
plate was fixed immediately
after wound creation.
UC untreated control
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3.7 In vitro treatment of B16F10 melanoma cells
and its effect on inhibition of lung metastasis (pretreatment)
In this study, B16F10 cells treated with a subtoxic
concentration of plain ETO and ETO-loaded micellar
formulations (IC25, 48 h) were injected to mice via the tail
vein to examine the effect formulations on the inhibition of
pulmonary metastatic nodule formation. The total number
of metastatic nodules found in the untreated control group
was 154.4±26.8, and based on this, the percent inhibition
in lung nodule formation of the formulation-treated group
was calculated and presented in Fig. 6.
The in vitro-treated B16F10 cells with plain ETO and
ETO-loaded micellar formulations exhibited a reduction in
the formation of pulmonary metastatic nodules, and the
maximum effect was seen in peptide-conjugated micelles
(P<0.001; Fig. 6). B16F10 cells treated with plain ETO
showed 47.92±11.78% inhibition in metastatic nodules,
which was lower compared with micellar formulations.
MPCL235 and MPCL570 micellar formulations showed
54.91±12.77% and 58.80±3.50% inhibitions in pulmonary
metastatic nodule formation, respectively. EILDV-conjugated
Fig. 5 Confocal images of B16F10 cells after 1-h incubation with 6-
coumarin-loaded micelles. Scale bar, 20 μm)
Fig. 4 Percent adhesion of B16F10 cells toward substrate-coated
plates after treatment with plain ETO and micellar formulations at
IC25 (48 h). Results are the mean ± SD, n=6 (**P<0.01 compared
with ETO)
Fig. 3 Percent B16F10 cell migration after treatment with plain ETO
and micellar formulations at IC25 concentrations. Results are the mean ±
SD, n=6 (***P<0.001, **P<0.01 compared with plain ETO)
Fig. 6 Percent inhibition of metastatic nodule formation after
inoculation of in vitro-treated B16F10 cells to C57BL/6 mice via the
tail vein. Results are the mean ± SD, n=5 (***P<0.001 compared
with plain ETO)
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micelles demonstrated close to 1.5-fold higher efficacies in the
prevention of metastasis compared with plain ETO.
3.8 In vivo treatment of B16F10 melanoma and its effect
on inhibition of lung metastasis (post-treatment)
In the post-treatment method, plain ETO and ETO-loaded
micellar formulations were injected by intravenous route on
the second day of B16F10 cell inoculation to C57BL/6
mice. The percent inhibition in metastatic nodule formation
after the 21st day of cell inoculation is represented in Fig. 7.
It was observed that all formulations showed their potential
toward inhibition in metastatic nodule formation. The
percent inhibition in nodule formation observed with plain
ETO was 36.72±7.85%, while MPCL235 and MPCL570
showed 48.60±10.04% and 53.99±9.42% nodule formations,
respectively (Fig. 7). EILDV-conjugated micelles compared
with plain ETO and non-conjugated micelles showed close
to 1.75- and 1.40-fold higher inhibitions in metastatic nodule
formation, respectively.
3.9 Histopathology
The histological examinations of lung sections are shown in
Fig. 8, in which the untreated control exhibited small- to
large-sized tumor islands which covered the entire lung
parenchyma and also blocked the lumen of the medium and
large blood vessels. Moreover, tumor cells penetrated the
middle coat of blood vessels and lodged in several blood
vessels. In the case of ETO, smaller-sized tumor islands
with a lesser extent of multiplicity were observed compared
with control. The MPCL235- and MPCL570-treated groups
showed a reduction in the number of tumor islands with
smaller sizes compared with the control. A greater extent of
reduction in size as well as the number of tumor islands was
observed in EILDV-conjugated micelles. In addition to this,
the blood vessels were found unblocked in EILDV-
conjugated micelles.
4 Discussion
One approach for increasing the site specificity of a
nanoparticulate carrier is to conjugate it with a ligand
which can interact with an overexpressed cell receptor.
Various molecules like folic acid, monoclonal antibodies,
and peptides have been reported as ligands for tumor
targeting of nanoparticles and liposomes (Sutton et al.
2007; Torchilin 2007). Despite promising outcomes showed
by the folate-conjugated nanocarrier for tumor targeting,
overexpression of folate receptors in normal tissues like
placenta and kidney was reported by immunochemistry
studies to impede the possible clinical translation of folate
bioconjugates for human use (Alexis et al. 2008). On the
other end, monoclonal antibodies possess two major draw-
backs as ligands for tumor targeting: their larger size and
nonspecific uptake by reticuloendothelial system (RES;
Aina et al. 2002). Compared with these, cell surface
binding peptides are considerably smaller in size, low
immunogenic, low toxic, and generally do not bind to RES
systems (Aina et al. 2002; Lopez-Barcons et al. 2004). In
the present study, we showed that the conjugation of
EILDV to polymeric micelles resulted into a receptor-
mediated uptake, which is helpful in the treatment of
metastasis.
MPCL570 and EPCL570 micelles showed higher percent
drug loading and particle size compared with MPCL235 and
EPCL235 micelles due to the influence of higher molecular
weight. The results obtained indicate that the drug encapsu-
lation efficiency depends on the copolymer composition and
the particle size. However, the percent drug loading can be
modulated by varying the hydrophilic-to-hydrophobic block
ratio (Kim and Lee 2001). Moreover, we found lower percent
drug loading in EILDV-conjugated micelles EPCL235 and
EPCL570 due to loss of the surface-bound drug during the
conjugation process. Up to this date, very few studies have
reported the effect of different surface densities of ligands
(cRGD, folate, and aptamers) on the intracellular uptake of
nanocarriers (Gu et al. 2008; Nasongkla et al. 2004; Zhao
and Yung 2008). These studies found that the surface density
of ligands plays an important role in optimum cellular uptake
mechanism. Pang et al. (2008) have reported the use of
monoclonal antibody OX-26 for brain delivery of PEG–PCL
micelles with various surface densities of OX-26. They
found that maximum blood–brain barrier permeability
Fig. 7 Percent inhibition of metastatic nodule formation in B16F10-
injected C56BL/6 mice after treatment with plain ETO and micellar
formulations at a dose of 2 mg/kg. Results are the mean ± SD, n=5
(**P<0.01, ***P<0.001 compared with ETO)
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surface area product (PS) and percentage of injected dose per
gram of brain were dependent on the OX26 densities on the
surface of polymersomes. On the effect of folate content on
targeting efficiency studied on KB cells, it was observed that
the maximum cellular uptake peaked at 65% folate content
(Zhao and Yung 2008). It has also been pointed out that the
high intracellular folate concentration may lead to saturation
and shut off folate receptor uptake, leading to reduced
intracellular uptake of micelles. However, in the case of
peptide-conjugated micelles, it is difficult to deduce the same
thing in terms of concentration, but the saturation and
regeneration of receptors may play an important role.
Cellular uptake studies conducted on B16F10 cell lines with
various surface densities of EILDV demonstrated similar
kinds of observations, and we found that upon increasing the
density up to 20%, a minor increase in cellular uptake
compared with the cellular uptake found with 10% surface
density of EILDV was shown. MTT assay at three different
time points (24, 48 and 72 h) showed time- and
concentration-dependent cytotoxicity. Plain ETO, due to its
solubilized state, leads to a rapid diffusion through the cell
membrane and showed higher cytotoxicity at 24- and
48-h incubation periods (Li et al. 2008; Zhao and Yung
2008). Compared with plain ETO, micellar formulations
showed a controlled-release behavior and showed much
lesser toxicity at the initial time point of incubation, i.e.,
24 h. EILDV-conjugated micelles exhibited the highest
cytotoxicity at 72-h incubation compared with plain ETO
and non-conjugated micellar formulations. This phenomenon
appeared to correspond reasonably well to the receptor-
medicated cellular uptake efficiency and is in agreement with
reports of previous studies and cellular uptake studies carried
out in the present work (Yang et al. 2008; Yoo and Park
2004; Zhao and Yung 2008).
It is known that migrating cells are less sensitive to
standard chemotherapy due to their decreased proliferation
rate (Douma et al. 2004; Lefranc et al. 2005). Therefore,
therapeutic drugs or drug-loaded carrier which can target
cell motility and invasion may appear to be important in
decreasing the mortality and mobility rates among cancer
patients. B16F10 cells after treatment with EILDV-
conjugated micelles showed greater inhibition in migration
compared with plain ETO and non-conjugated micelles at a
similar inhibitory concentration, i.e., IC25. These might be
due to the effect of ETO on the changes in cell cytoskeleton
of B16F10 cells after drug exposure. It was reported that
ETO promoted the changes in the distribution of tubulin in
HL-60 cells with significant changes in cell morphology
(Grzanka and Grzanka 2003). We supposed that the
alteration in cell morphology due to ETO resulted into
inhibition in the migration of B16F10 cells.
EILDV, after conjugation on the surface of micelles,
showed a significant reduction in the adhesion of B16F10
cells toward substrate-coated plates, implying no alternation
in biological activity after conjugation. In addition, we also
found a reduction in adhesion of B16F10 cells treated with
plain ETO and non-conjugated micellar formulations,
which suggests that ETO might have some role in the
prevention of adhesion of B16F10 cells. Exposure of ETO
to the cells leads to apoptosis and gross changes in cell
shape Kook et al. (2000). Moreover, a decline in focal
adhesion sites was also seen in ETO-treated Rat-1 cells due
to cleavage of the Crk-associated substrate by caspase-3. It
was believed that the effect of ETO on the reduction in
Fig. 8 Histology section of
lungs (pretreatment method)
stained with hematoxilin and
eosin. Black arrow indicates
pulmonary metastatic nodule
formation
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focal adhesion sites might have prevented the adhesion of
B16F10 cells to substrate-coated plates. EPCL235-P and
EPCL570-P micelles also showed a reduction in cell
adhesion in the absence of ETO, which further supports
the role of EILDV in the prevention of cell adhesion.
Confocal microscopy analysis of 6-coumarin-loaded
micelles demonstrated an enhanced uptake of EPCL235
and EPCL570 micelles by B16F10 cells compared with
non-conjugated micelles, MPCL235 and MPCL570, attribut-
ing greater intracellular delivery due to receptor-mediated
endocytosis.
Experimental metastasis study conducted using highly
metastatic B16F10 cells was reported to produce pulmo-
nary metastatic nodules in lungs after intravenous injection
of cells (Cameron et al. 2000; Gude et al. 1996). In actual
metastatic process which is observed in subcutaneously
developed tumor, several processes such as primary
invasion, transport into circulation, survival in circulation,
arrest in the capillary bed of an organ, extravasation into the
parenchyma, and several other steps are involved. Com-
pared with these, many of these steps are not seen in the
experimental metastasis model. Although, this model is
very useful in investigating the process of organ specificity
of tumor cells involving homing to the lung and the
subsequent cell–cell interaction. As metastatic cells need to
attach themselves to lung basement membrane before they
grow into nodules, cell adhesion plays a vital part in the
metastatic spreading of B16 melanoma (Gude et al. 1996).
Experimental metastasis conducted by two different techni-
ques, i.e., pretreatment and post-treatment models, showed
the effectiveness of micellar formulations over plain drug to
prevent the colonization of B16F10 cells in the lung. The
results obtained implies that ETO and ETO-loaded micellar
formulations might have interacted directly or indirectly
with tumor cell (B16F10 cell) surface receptors involved in
adhesion to lung basement membrane (Gude et al. 1996).
EILDV-conjugated micelles EPCL235 and EPCL570
exhibited higher inhibition in the formation of pulmonary
metastatic nodules compared with plain ETO and non-
conjugated micelles due to its interaction with cell surface
receptors present on B16F10 cells. Pretreatment method
exhibited higher inhibition in pulmonary metastatic nodule
formation compared with the post-treatment method.
However, it is difficult to correlate each other due to the
difference in treatment and the dose of drug given in the
intravenous route. Both pretreatment and post-treatment
methods justify that two different situations exist in cancer
patients. The pretreatment method describes the situation in
which a patient is detected with primary tumor and receives
chemotherapy, while the post-treatment method entails a
situation in which metastasis has already been detected and
then chemotherapy has started. Furthermore, liposomal
pentoxifyline and niosomal cisplatin demonstrated higher
antimetastatic activity compared with plain drug, indicating
the usefulness of nanocarrier in treatment of metastasis
(Gude et al. 2002; Sant et al. 2000). The market-available
DOXIL® (pegylated doxorubicin liposomes) which is used
in metastasis was not that much defined by clinical trials
due to a poor understanding of its role in the prevention of
metastasis. It is believed that the antimetastasis effect was
rather due to the inhibition in growth of the primary tumor
(Zhang et al. 2008). It was also suggested that for complete
eradication of pulmonary metastasis, surgical removal of
primary tumor plus multiple injections of pegylated
doxorubicin liposomes are needed. In this situation,
micelles conjugated with antimetastatic peptides like
EILDV can play a major role in recognition of tumor cells
which have been already detached from the primary tumor
site and under process of metastasis.
5 Conclusion
In conclusion, EILDV-conjugated micelle was more effec-
tive in the treatment of metastasis compared with plain
ETO. The in vitro cell line studies conducted on highly
metastatic B16F10 cells demonstrated the superior antimi-
gratory and antiadhesive activity of EILDV-conjugated
micelles by virtue of their receptor-mediated endocytosis
mechanism. Furthermore, experimental metastasis assay
elucidated the potential of EILDV-conjugated micelles in
the prevention and cure of metastasis, a condition which is
considered difficult to eradicate completely by conventional
chemotherapy. Overall, EILDV-conjugated micelles loaded
with the anticancer drug ETO could open new opportunities
for the effective treatment of metastasis.
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